OneMedNet Partners with Inka Health on Pilot to Fuel PNKP Inhibitor Development Using AI
OneMedNet has entered a pilot collaboration with Onco-Innovations’ Inka Health to grant access to its iRWD™ platform powered by Palantir Foundry for U.S. oncology real-world data. The deal aims to accelerate development of Onco’s PNKP Inhibitor targeting PTEN/SHP1-deficient cancers, optimizing patient responder identification and reducing clinical and regulatory risk.
1. Collaboration Overview
OneMedNet and Inka Health, a subsidiary of Onco-Innovations, have launched a selective pilot program granting access to OneMedNet’s iRWD™ platform. The pilot follows a technical evaluation and qualifies Inka Health to tap into U.S. real-world oncology data for drug development use cases.
2. Focus on PNKP Inhibitor Technology
The partnership centers on advancing Onco-Innovations’ proprietary PNKP Inhibitor Technology aimed at PTEN/SHP1-deficient tumors. Key objectives include identifying patient responders, exploring indications beyond advanced metastatic colorectal cancer, and generating evidence to inform clinical and regulatory decision-making.
3. iRWD™ Platform Capabilities
The Palantir Foundry-powered iRWD™ platform combines regulatory-grade, multi-modal real-world data with AI-augmented search to locate rare molecular cohorts at scale. Its longitudinal clinical context and causal-inference tools support both trial recruitment and SynoGraph™ AI model development for safety and efficacy predictions.
4. Strategic Implications
By leveraging real-world data and advanced analytics, OneMedNet expects to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation. This collaboration could enhance OneMedNet’s service value proposition and drive future revenue growth through expanded oncology partnerships.